關(guān)鍵詞： GSK Texas AM 流感疫苗
2013年3月27日訊 /生物谷BIOON/ -- GSK公司與Texas A&M公司聯(lián)合投入總額高達(dá)9100萬美元資金來建立一個(gè)新型流感疫苗中心,。該中心將用細(xì)胞培養(yǎng)基取代傳統(tǒng)的雞胚來制備疫苗,。目前美國僅有三個(gè)類似的中心在建。該中心將能夠在流感爆發(fā)的四個(gè)月內(nèi)生產(chǎn)高達(dá)5000萬份流感疫苗,。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
As part of an ambitious effort to prep for a future pandemic, GlaxoSmithKline ($GSK) and Texas A&M are teaming up to build a $91 million flu vaccine manufacturing center in the Lone Star state that will rely on cell-culture lines rather than chicken eggs. One of only three such centers planned for the U.S., it's designed to be able to produce up to 50 million doses of a pandemic flu vaccine within four months of an outbreak. That's much faster than the old tech in use today. With typical Texan braggadocio, Governor Rick Perry said that the center would add $41 billion in new spending over 25 years while producing 6,800 direct and indirect jobs. Such figures rarely prove accurate, but who's counting in a slowpoke economy?
(責(zé)任編輯：lili.zhao)
